135 related articles for article (PubMed ID: 8344908)
21. Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII.
Iino M; Foster DC; Kisiel W
Arch Biochem Biophys; 1998 Apr; 352(2):182-92. PubMed ID: 9587405
[TBL] [Abstract][Full Text] [Related]
22. Expression of human soluble tissue factor in yeast and enzymatic properties of its complex with factor VIIa.
Shigematsu Y; Miyata T; Higashi S; Miki T; Sadler JE; Iwanaga S
J Biol Chem; 1992 Oct; 267(30):21329-37. PubMed ID: 1400445
[TBL] [Abstract][Full Text] [Related]
23. The role of phospholipids and the factor VII Gla-domain in the interaction of factor VII with tissue factor.
Wildgoose P; Jørgensen T; Komiyama Y; Nakagaki T; Pedersen A; Kisiel W
Thromb Haemost; 1992 Jun; 67(6):679-85. PubMed ID: 1509409
[TBL] [Abstract][Full Text] [Related]
24. Binding of human factors VII and VIIa to a human bladder carcinoma cell line (J82). Implications for the initiation of the extrinsic pathway of blood coagulation.
Sakai T; Lund-Hansen T; Paborsky L; Pedersen AH; Kisiel W
J Biol Chem; 1989 Jun; 264(17):9980-8. PubMed ID: 2785997
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
[TBL] [Abstract][Full Text] [Related]
26. FVIIa derivatives obtained by autolytic and controlled cathepsin G mediated cleavage.
Nicolaisen EM; Thim L; Jacobsen JK; Nielsen PF; Mollerup I; Jørgensen T; Hedner U
FEBS Lett; 1993 Feb; 317(3):245-9. PubMed ID: 8425611
[TBL] [Abstract][Full Text] [Related]
27. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor.
Sorensen BB; Persson E; Freskgârd PO; Kjalke M; Ezban M; Williams T; Rao LV
J Biol Chem; 1997 May; 272(18):11863-8. PubMed ID: 9115245
[TBL] [Abstract][Full Text] [Related]
28. Cooperative interaction of divalent metal ions, substrate, and tissue factor with factor VIIa.
Butenas S; Lawson JH; Kalafatis M; Mann KG
Biochemistry; 1994 Mar; 33(11):3449-56. PubMed ID: 8136382
[TBL] [Abstract][Full Text] [Related]
29. Factor VIIa's first epidermal growth factor-like domain's role in catalytic activity.
Jin J; Chang J; Chang JY; Kelley RF; Stafford DW; Straight DL
Biochemistry; 1999 Jan; 38(4):1185-92. PubMed ID: 9930978
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human factor VIIa-tissue factor activity by placental anticoagulant protein.
Kondo S; Noguchi M; Funakoshi T; Fujikawa K; Kisiel W
Thromb Res; 1987 Nov; 48(4):449-59. PubMed ID: 2965430
[TBL] [Abstract][Full Text] [Related]
31. Tissue factor potentiates the factor VIIa-catalyzed hydrolysis of an ester substrate.
Higashi S; Nishimura H; Fujii S; Takada K; Iwanaga S
J Biol Chem; 1992 Sep; 267(25):17990-6. PubMed ID: 1517232
[TBL] [Abstract][Full Text] [Related]
32. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
Zhang E; St Charles R; Tulinsky A
J Mol Biol; 1999 Feb; 285(5):2089-104. PubMed ID: 9925787
[TBL] [Abstract][Full Text] [Related]
33. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa.
Rao LV; Rapaport SI; Hoang AD
Blood; 1993 May; 81(10):2600-7. PubMed ID: 8490170
[TBL] [Abstract][Full Text] [Related]
34. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function. Analysis of a mutant with a selective deficiency in activity.
Neuenschwander PF; Morrissey JH
J Biol Chem; 1992 Jul; 267(20):14477-82. PubMed ID: 1629232
[TBL] [Abstract][Full Text] [Related]
35. Dimerization of tissue factor supports solution-phase autoactivation of factor VII without influencing proteolytic activation of factor X.
Doñate F; Kelly CR; Ruf W; Edgington TS
Biochemistry; 2000 Sep; 39(37):11467-76. PubMed ID: 10985793
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the interaction between the light chain of factor VIIa and tissue factor.
Persson E
FEBS Lett; 1997 Aug; 413(2):359-63. PubMed ID: 9280313
[TBL] [Abstract][Full Text] [Related]
37. Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor.
Huang H; Norledge BV; Liu C; Olson AJ; Edgington TS
Biochemistry; 2003 Sep; 42(36):10619-26. PubMed ID: 12962485
[TBL] [Abstract][Full Text] [Related]
38. Generation of Gla-domainless FVIIa by cathepsin G-mediated cleavage.
Nicolaisen EM; Petersen LC; Thim L; Jacobsen JK; Christensen M; Hedner U
FEBS Lett; 1992 Jul; 306(2-3):157-60. PubMed ID: 1633870
[TBL] [Abstract][Full Text] [Related]
39. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
Rao LV; Ruf W
Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
[TBL] [Abstract][Full Text] [Related]
40. Characterization of factor VII association with tissue factor in solution. High and low affinity calcium binding sites in factor VII contribute to functionally distinct interactions.
Ruf W; Kalnik MW; Lund-Hansen T; Edgington TS
J Biol Chem; 1991 Aug; 266(24):15719-25. PubMed ID: 1874730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
